SA520412335B1 - مشتقات أوكسي فلورو ببريدين كمثبط كيناز - Google Patents

مشتقات أوكسي فلورو ببريدين كمثبط كيناز

Info

Publication number
SA520412335B1
SA520412335B1 SA520412335A SA520412335A SA520412335B1 SA 520412335 B1 SA520412335 B1 SA 520412335B1 SA 520412335 A SA520412335 A SA 520412335A SA 520412335 A SA520412335 A SA 520412335A SA 520412335 B1 SA520412335 B1 SA 520412335B1
Authority
SA
Saudi Arabia
Prior art keywords
oxy
kinase inhibitor
fluoropiperidine
derivatives
chemical formula
Prior art date
Application number
SA520412335A
Other languages
English (en)
Inventor
وو كيم إن
هي لي جون
اه جون سون
يون كيم نام
Original Assignee
دايوونج فارماسوتيكال كو.، ليمتد.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by دايوونج فارماسوتيكال كو.، ليمتد. filed Critical دايوونج فارماسوتيكال كو.، ليمتد.
Publication of SA520412335B1 publication Critical patent/SA520412335B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

يتعلق الاختراع الحالي بمركب ممثل بالصيغة الكيميائية التالية 1، أو ملح salt مقبول صيدلانياً منه، ويمكن استخدام المركب الخاص بالاختراع الحالي بشكل مفيد للوقاية من أو علاج الأمراض prevention or treatment of diseases المرتبطة الإجراءات المثبطة للكيناز kinase inhibitory. الصيغة الكيميائية 1
SA520412335A 2017-12-28 2020-06-25 مشتقات أوكسي فلورو ببريدين كمثبط كيناز SA520412335B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170183061 2017-12-28

Publications (1)

Publication Number Publication Date
SA520412335B1 true SA520412335B1 (ar) 2022-09-19

Family

ID=67067864

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520412335A SA520412335B1 (ar) 2017-12-28 2020-06-25 مشتقات أوكسي فلورو ببريدين كمثبط كيناز

Country Status (32)

Country Link
US (1) US11339167B2 (ar)
EP (1) EP3733673B1 (ar)
JP (1) JP6995428B2 (ar)
KR (2) KR102318929B1 (ar)
CN (1) CN111527091B (ar)
AU (1) AU2018394997B2 (ar)
BR (1) BR112020013141B1 (ar)
CA (1) CA3084962C (ar)
CL (1) CL2020001752A1 (ar)
CO (1) CO2020007162A2 (ar)
DO (1) DOP2020000112A (ar)
EC (1) ECSP20035590A (ar)
ES (1) ES2922633T3 (ar)
HR (1) HRP20221043T1 (ar)
HU (1) HUE059580T2 (ar)
IL (1) IL275207B (ar)
LT (1) LT3733673T (ar)
MA (1) MA51431B1 (ar)
MX (1) MX2020006799A (ar)
MY (1) MY194468A (ar)
NZ (1) NZ764644A (ar)
PE (1) PE20201146A1 (ar)
PH (1) PH12020551013A1 (ar)
PL (1) PL3733673T3 (ar)
PT (1) PT3733673T (ar)
RS (1) RS63515B1 (ar)
RU (1) RU2758370C1 (ar)
SA (1) SA520412335B1 (ar)
SG (1) SG11202004917UA (ar)
SI (1) SI3733673T1 (ar)
TN (1) TN2020000082A1 (ar)
WO (1) WO2019132562A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200629A (en) 2017-08-01 2024-01-06 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
RS63515B1 (sr) * 2017-12-28 2022-09-30 Daewoong Pharmaceutical Co Ltd Derivat oksi-fluoropiperidina kao inhibitor kinaze
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
CN113498352A (zh) 2019-01-23 2021-10-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的咪唑并[1,5-a]吡啶、1,2,4-三唑并[4,3-a]吡啶和咪唑并[1,5-a]吡嗪
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
CN115244055A (zh) * 2020-01-21 2022-10-25 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
WO2021147952A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并吡咯类化合物
TW202214643A (zh) * 2020-09-22 2022-04-16 大陸商江蘇先聲藥業有限公司 嘧啶并吡咯類化合物
CN114315838A (zh) * 2020-09-30 2022-04-12 江苏先声药业有限公司 嘧啶并吡咯类化合物
WO2023165562A1 (zh) * 2022-03-02 2023-09-07 南京明德新药研发有限公司 含氮杂环类化合物及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2009026107A1 (en) 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2011000661A (es) 2008-07-16 2011-05-25 Pharmacyclics Inc Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos.
WO2010129053A2 (en) 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
LT2975042T (lt) 2010-06-23 2019-01-25 Hanmi Science Co., Ltd. Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui
JP5914667B2 (ja) 2011-09-22 2016-05-11 ファイザー・インク ピロロピリミジンおよびプリン誘導体
JP6215938B2 (ja) 2012-08-06 2017-10-18 エイシア バイオサイエンシーズ インコーポレイテッド プロテインキナーゼの阻害剤としての新規ピロロピリミジン化合物
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
RU2015137298A (ru) 2013-03-05 2017-04-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
RU2650512C2 (ru) 2013-09-18 2018-04-16 Бейджин Ханми Фармасьютикал Ко., Лтд. Соединение, ингибирующее активности киназ ВТК и/или JAK3
EP3318565B1 (en) 2013-12-05 2021-04-14 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
CN105732637B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
AU2016369584A1 (en) 2015-12-16 2018-07-19 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
JP2019519579A (ja) 2016-06-30 2019-07-11 デウン ファーマシューティカル カンパニー リミテッド キナーゼ阻害剤としてのピラゾロピリミジン誘導体
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
RS63515B1 (sr) * 2017-12-28 2022-09-30 Daewoong Pharmaceutical Co Ltd Derivat oksi-fluoropiperidina kao inhibitor kinaze
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체

Also Published As

Publication number Publication date
CN111527091B (zh) 2023-03-28
MA51431A (fr) 2021-04-07
MA51431B1 (fr) 2022-08-31
CA3084962A1 (en) 2019-07-04
MY194468A (en) 2022-11-30
SI3733673T1 (sl) 2022-09-30
CN111527091A (zh) 2020-08-11
KR102318929B1 (ko) 2021-10-28
HRP20221043T1 (hr) 2022-11-11
PL3733673T3 (pl) 2022-09-26
PT3733673T (pt) 2022-07-18
ECSP20035590A (es) 2020-07-31
RU2758370C1 (ru) 2021-10-28
RS63515B1 (sr) 2022-09-30
PH12020551013A1 (en) 2021-08-16
JP2021506818A (ja) 2021-02-22
HUE059580T2 (hu) 2022-11-28
AU2018394997B2 (en) 2021-02-04
BR112020013141A2 (pt) 2021-02-23
MX2020006799A (es) 2020-09-03
PE20201146A1 (es) 2020-10-26
KR20210062618A (ko) 2021-05-31
WO2019132562A1 (ko) 2019-07-04
NZ764644A (en) 2023-06-30
CA3084962C (en) 2022-08-09
CO2020007162A2 (es) 2020-06-19
IL275207B (en) 2022-09-01
ES2922633T3 (es) 2022-09-19
IL275207A (en) 2020-07-30
SG11202004917UA (en) 2020-06-29
KR20190080803A (ko) 2019-07-08
TN2020000082A1 (en) 2022-01-06
AU2018394997A1 (en) 2020-06-11
CL2020001752A1 (es) 2020-11-27
JP6995428B2 (ja) 2022-01-14
EP3733673A1 (en) 2020-11-04
KR102592083B1 (ko) 2023-10-20
US11339167B2 (en) 2022-05-24
DOP2020000112A (es) 2020-08-31
LT3733673T (lt) 2022-08-10
BR112020013141B1 (pt) 2022-03-15
US20200308177A1 (en) 2020-10-01
EP3733673B1 (en) 2022-06-29
EP3733673A4 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12019500480A1 (en) Pyridine compound
MY193239A (en) Novel b-lactamase inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
SG11201803867TA (en) Sodium channel blocker
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.